JPMorgan Hikes Eli Lilly Stock Target on Strong Drug Demand

JPMorgan analyst Chris Schott raised the price target for Eli Lilly (LLY) to $1,200 from $1,100, maintaining an Overweight rating. The adjustment comes amid sustained strong demand for the company's leading diabetes and obesity drugs.

Rating Change

• Previous Rating: Overweight with a $1,100 price target.
• Current Rating: Overweight with a $1,200 price target.

Analyst Rationale

Analyst Chris Schott believes that demand for Eli Lilly's GLP-1 drugs (such as Mounjaro and Zepbound) shows no signs of slowing. Additionally, the company's pipeline of future products reinforces confidence in strong revenue and earnings growth in the coming years.

Context

The price target hike follows a series of record financial results for the company. Other Wall Street analysts are also turning positive on the stock, with LLY receiving a 'Buy' rating from the majority. Schott also covers Pfizer (PFE) and Teva Pharmaceutical Industries.

What to Make of It

The price target increase from JPMorgan reflects growing confidence in Eli Lilly's ability to sustain its growth momentum, supported by its leading products in the diabetes and obesity markets. However, investors should monitor competitive and pricing developments.